SightfileU.S. market data from official filings

TARSUS PHARMACEUTICALS INC (TARS)

Name: TARSUS PHARMACEUTICALS INC (TARS) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001819790 · EDGAR filings · Updated 2026-07-13

TARSUS PHARMACEUTICALS INC (TARS) has reported institutional ownership of 104.9%, with 253 institutional managers holding positions valued at $3.17B per the latest 13F reporting period.

Institutional ownership

104.9%

Institutional managers

253

Reported 13F value

$3.17B

Insider activity

66 trans.

−$15.8M net selling

Latest updates

2026-07-13 — Current report (8-K) filed
2026-07-08 — Current report (8-K) filed
2026-06-29 — Insider transaction reported (Form 4)
2026-06-29 — Insider transaction reported (Form 4)
2026-06-29 — Insider transaction reported (Form 4)
2026-06-29 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, TARSUS PHARMACEUTICALS INC has 253 institutional holders and institutional ownership of 104.9%.

Insider activity

Insiders reported 66 transactions (0 buys, 45 sells) across 14 reporting insiders, with a net reported value of −$15.8M.

Related companies

DYNE THERAPEUTICS INC (DYN) · STRUCTURE THERAPEUTICS INC (GPCR) · CORCEPT THERAPEUTICS INC (CORT) · IDEAYA BIOSCIENCES INC (IDYA) · ARCUTIS BIOTHERAPEUTICS INC (ARQT) · ACADIA HEALTHCARE COMPANY IN (ACHC)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-13.